Patient Recruitment In Phase II Breast Cancer Trial With MESUPRON(R) Successfully Com

[News]

WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) announced today that it has successfully completed patient recruitment in the clinical Phase II trial with its oral drug candidate MESUPRON® in first line treatment of patients with HER2-receptor negative1) metastatic breast cancer...

More... (http://www.medicalnewstoday.com/releases/224311.php)